- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
- Legal category
Treatment must be initiated under the supervision of a specialist in childhood and/or adolescent behavioural disorders.
Pre-treatment screening:Prior to prescribing, it is necessary to conduct a baseline evaluation of a patient's cardiovascular status including blood pressure and heart rate. A comprehensive history should document concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre-treatment height and weight on a growth chart (see sections 4.3 and 4.4)
Ongoing monitoring:Growth, psychiatric and cardiovascular status should be continuously monitored (see also Section 4.4).• Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months;• height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart;• development of de novo or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then least every 6 months and at every visit.Patients should be monitored for the risk of diversion, misuse and abuse of methylphenidate.Dose titration:Careful dose titration is necessary at the start of treatment with methylphenidate. Dose titration should be started at the lowest possible dose. This is normally achieved using an immediate release formulation taken in divided doses. The recommended starting daily dose is 5 mg once daily or twice daily (e.g. at breakfast and lunch), increasing if necessary by weekly increments of 5-10 mg in the daily dose according to tolerability and degree of efficacy observed. Equasym XL 10 mg once daily may be used in place of immediate release methylphenidate hydrochloride 5 mg twice daily from the beginning of treatment where the treating physician considers that twice daily dosing is appropriate from the outset and twice daily treatment administration is impracticable.The maximum daily dose of methylphenidate hydrochloride is 60 mg.For doses not realisable/practicable with this strength, other strengths of this medicinal product and other methylphenidate containing products are available.Patients Currently Using Methylphenidate: Patients established on an immediate release methylphenidate hydrochloride formulation may be switched to the milligram equivalent daily dose of Equasym XL.Equasym XL should not be taken too late in the morning as it may cause disturbances in sleep. If the effect of the medicinal product wears off too early in the late afternoon or evening, disturbed behaviour and/or inability to go to sleep may recur. A small dose of an immediate-release methylphenidate hydrochloride tablet late in the day may help to solve this problem. In that case, it could be considered that adequate symptom control might be achieved with a twice daily immediate release methylphenidate regimen. The pros and cons of a small evening dose of immediate-release methylphenidate versus disturbances in falling asleep should be considered. Treatment should not continue with Equasym XL if an additional late dose of immediate-release methylphenidate is required, unless it is known that the same extra dose was also required for a conventional immediate-release regimen at equivalent breakfast/lunchtime dose. The regimen that achieves satisfactory symptom control with the lowest total daily dose should be employed.Equasym XL should be given in the morning before breakfast.The capsules may be swallowed whole with the aid of liquids, or alternatively, the capsule may be opened and the capsule contents sprinkled onto a small amount (tablespoon) of applesauce and given immediately, and not stored for future use. Drinking some fluids, e.g. water, should follow the intake of the sprinkles with applesauce. The capsules and the capsule contents must not be crushed or chewed.
Long-term (more than 12 months) use in children and adolescents:The safety and efficacy of long term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long term usefulness of the drug for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child's condition (preferable during times of school holidays). Improvement may be sustained when the drug is either temporarily or permanently discontinued.
Dose reduction and discontinuationTreatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued.
AdultsMethylphenidate is not licensed for use in adults in ADHD. Safety and efficacy have not been established in this age group.
ElderlyMethylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group.
Children under 6 years of ageMethylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
Long-term use (more than 12 months) in children and adolescentsThe safety and efficacy of long term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. Patients on long-term therapy (i.e. over 12 months) must have careful ongoing monitoring according to the guidance in sections 4.2 and 4.4. for cardiovascular status, growth, appetite, development of de novo or worsening of pre-existing psychiatric disorders. Psychiatric disorders to monitor for are described below, and include (but are not limited to) motor or vocal tics, aggressive or hostile behaviour, agitation, anxiety, depression, psychosis, mania, delusions, irritability, lack of spontaneity, withdrawal and excessive perseveration.The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long term usefulness of the drug for the individual patient with trial periods off medication to assess the patient's functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child's condition (preferably during times of school holidays). Improvement may be sustained when the drug is either temporarily or permanently discontinued.
Use in adultsMethylphenidate is not licensed for use in adults with ADHD. Safety and efficacy have not been established in this age group.
Use in the elderlyMethylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group.
Use in children under 6 years of ageMethylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.
Cardiovascular statusPatients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exertional chest pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation.Analyses of data from clinical trials of methylphenidate in children and adolescents with ADHD showed that patients using methylphenidate may commonly experience changes in diastolic and systolic blood pressure of over 10 mmHg relative to controls. The short- and long-term clinical consequences of these cardiovascular effects in children and adolescents are not known, but the possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate. See section 4.3 for conditions in which methylphenidate treatment in contraindicated.Cardiovascular status should be carefully monitored. Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months.The use of methylphenidate is contraindicated in certain pre-existing cardiovascular disorders unless specialist paediatric cardiac advice has been obtained (see Section 4.3 'Contraindications').
Sudden death and pre-existing cardiac structural abnormalities or other serious cardiac disordersSudden death has been reported in association with the use of stimulants of the central nervous system at usual doses in children, some of whom had cardiac structural abnormalities or other serious heart problems. Although some serious heart problems alone may carry an increased risk of sudden death, stimulant products are not recommended in children or adolescents with known cardiac structural abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medicine.
Misuse and Cardiovascular EventsMisuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events.
Cerebrovascular disordersSee section 4.3 for cerebrovascular conditions in which methylphenidate treatment in contraindicated. Patients with additional risk factors (such as a history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed at every visit for neurological signs and symptoms after initiating treatment with methylphenidate.Cerebral vasculitis appears to be a very rare idiosyncratic reaction to methylphenidate exposure. There is little evidence to suggest that patients at higher risk can be identified and the initial onset of symptoms may be the first indication of an underlying clinical problem. Early diagnosis, based on a high index of suspicion, may allow the prompt withdrawal of methylphenidate and early treatment. The diagnosis should therefore be considered in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during methylphenidate therapy. These symptoms could include severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory.Treatment with methylphenidate is not contraindicated in patients with hemiplegic cerebral palsy.
Psychiatric disordersCo-morbidity of psychiatric disorders in ADHD is common and should be taken into account when prescribing stimulant products. In the case of emergent psychiatric symptoms or exacerbation of pre-existing psychiatric disorders, methylphenidate should not be given unless the benefits outweigh the risks to the patient.Development or worsening of psychiatric disorders should be monitored at every adjustment of dose, then at least every 6 months, and at every visit; discontinuation of treatment may be appropriate.
Exacerbation of pre-existing Psychotic or manic symptomsIn psychotic patients, administration of methylphenidate may exacerbate symptoms of behavioural disturbance and thought disorder.
Emergence of new psychotic or manic symptomsTreatment-emergent psychotic symptoms (visual/tactile/auditory hallucinations and delusions) or mania in children and adolescents without prior history of psychotic illness or mania can be caused by methylphenidate at usual doses. If manic or psychotic symptoms occur, consideration should be given to a possible causal role for methylphenidate, and discontinuation of treatment may be appropriate.
Aggressive or hostile behaviourThe emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.
Suicidal tendencyPatients with emergent suicidal ideation or behaviour during treatment for ADHD should be evaluated immediately by their physician. Consideration should be given to the exacerbation of an underlying psychiatric condition and to a possible causal role of methylphenidate treatment. Treatment of an underlying psychiatric condition may be necessary and consideration should be given to a possible discontinuation of methylphenidate.
TicsMethylphenidate is associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette's syndrome has also been reported. Family history should be assessed and clinical evaluation for tics or Tourette's syndrome in children should precede use of methylphenidate. Patients should be regularly monitored for the emergence or worsening of tics during treatment with methylphenidate. Monitoring should be at every adjustment of dose and then at least every 6 months or every visit.
Anxiety, agitation or tensionMethylphenidate is associated with the worsening of pre-existing anxiety, agitation or tension. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should be regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 month or every visit.
Forms of bipolar disorderParticular care should be taken in using methylphenidate to treat ADHD in patients with comorbid bipolar disorder (including untreated Type I Bipolar Disorder or other forms of bipolar disorder) because of concern for possible precipitation of a mixed/manic episode in such patients. Prior to initiating treatment with methylphenidate, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. Close ongoing monitoring is essential in these patients (see above 'Psychiatric Disorders' and section 4.2). Patients should be monitored for symptoms at every adjustment of dose, then at least every 6 months and at every visit.
GrowthModerately reduced weight gain and growth retardation have been reported with the long-term use of methylphenidate in children.The effects of methylphenidate on final height and final weight are currently unknown and being studied.Growth should be monitored during methylphenidate treatment: height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
SeizuresMethylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patient with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new-onset seizures occur, methylphenidate should be discontinued.
Abuse, misuse and diversionPatients should be carefully monitored for the risk of diversion, misuse and abuse of methylphenidate.Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.Chronic abuse of methylphenidate can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially in response to parenteral abuse.Patient age, the presence of risk factors for substance use disorder (such as co-morbid oppositional-defiant or conduct disorder and bipolar disorder), previous or current substance abuse should all be taken into account when deciding on a course of treatment for ADHD. Caution is called for in emotionally unstable patients, such as those with a history of drug or alcohol dependence, because such patients may increase the dosage on their own initiative.For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non-stimulant treatment should be considered.
WithdrawalCareful supervision is required during drug withdrawal, since this may unmask depression as well as chronic over-activity. Some patients may require long-term follow up.Careful supervision is required during withdrawal from abusive use since severe depression may occur.
FatigueMethylphenidate should not be used for the prevention or treatment of normal fatigue states.
Excipients: sucrose intoleranceThis medicinal product contains sucrose: patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.
Choice of methylphenidate formulationThe choice of formulation of methylphenidate-containing product will have to be decided by the treating specialist on an individual basis and depends on the intended duration of effect.
Drug screeningThis product contains methylphenidate which may induce a false positive laboratory test for amphetamines, particularly with immunoassay screen test.
Renal or hepatic insufficiencyThere is no experience with the use of methylphenidate in patients with renal or hepatic insufficiency.
Haematological effectsThe long-term safety of treatment with methylphenidate is not fully known. In the event of Leukopenia, thrombocytopenia, anaemia or other alterations, including those indicative of serious renal or hepatic disorders, discontinuation of treatment should be considered.
Pharmacokinetic interactionIt is not known how methylphenidate may affect plasma concentrations of concomitantly administered drugs. Therefore, caution is recommended at combining methylphenidate with other drugs, especially those with a narrow therapeutic window.Methylphenidate is not metabolised by cytochrome P450 to a clinically relevant extent. Inducers or inhibitors of cytochrome P450 are not expected to have any relevant impact on methylphenidate pharmacokinetics. Conversely, the d- and l- enantiomers of methylphenidate do not relevantly inhibit cytochrome P450 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A.However, there are reports indicating that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g. phenobarbital, phenytoin, primidone) and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). When starting or stopping treatment with methylphenidate, it may be necessary to adjust the dosage of these drugs already being taken and establish drug plasma concentrations (or for coumarin, coagulation times).
Anti-hypertensive drugsMethylphenidate may decrease the effectiveness of drugs used to treat hypertension.
Use with drugs that elevate blood pressureCaution is advised in patients being treated with methylphenidate with any other drug that can also elevate blood pressure (see also sections on cardiovascular and cerebrovascular conditions in Section 4.4 Warnings and Precautions for use).Because of possible hypertensive crisis, methylphenidate is contraindicated in patients being treated (currently or within the preceding 2 weeks) with non-selective, irreversible MAO-inhibitors (see section 4.3 Contraindications).
Use with alcoholAlcohol may exacerbate the CNS adverse reactions of psychoactive drugs, including methylphenidate. It is therefore advisable for patients to abstain from alcohol during treatment.
Use with halogenated anaestheticsThere is a risk of sudden blood pressure increase during surgery. If surgery is planned, methylphenidate treatment should not be used on the day of surgery.
Use with centrally acting alpha-2 agonists (e.g. clonidine)Serious adverse events, including sudden death, have been reported in concomitant use with clonidine. The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systematically evaluated.
Use with dopaminergic drugsCaution is recommended when administering methylphenidate with dopaminergic drugs, including antipsychotics. Because a predominant action of methylphenidate is to increase extracellular dopamine levels, methylphenidate may be associated with pharmacodynamic interactions when co-administered with direct and indirect dopamine agonists (including DOPA and tricyclic antidepressants) or with dopamine antagonists including antipsychotics.
PregnancyThere is limited amount of data from the use of methylphenidate in pregnant women.Cases of neonatal cardiorespiratory toxicity, specifically fetal tachycardia and respiratory distress have been reported in spontaneous case reports. Studies in animals have only shown reproductive toxicity at maternally toxic doses (see Section 5.3).Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy.
LactationMethylphenidate has been found in the breast-milk of a woman treated with methylphenidate.There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate. A risk to the suckling child cannot be excluded.A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
|o The medicine has been prescribed to treat a medical problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and o It was not affecting your ability to drive safely.|
|System Organ Class||Adverse Drug Reaction|
|Infections and infestations|
|Blood and lymphatic system disorders|
|Very rare:||anaemia, leucopenia, thrombocytopenia, thrombocytopenic purpura|
|Immune System Disorders|
|Uncommon:||hypersensitivity reactions such as angioneurotic oedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticarias, pruritis, rashes and eruptions|
|Metabolism and nutrition disorders*|
|Common:||anorexia, decreased appetite, moderately reduced weight and height gain during prolonged use in children*|
|Very common:||insomnia, nervousness|
|Common:||anorexia, affect lability, aggression*, agitation*, anxiety*, depression*, irritability, abnormal behaviour, bruxism|
|Uncommon:||psychotic disorders*, auditory, visual, and tactile hallucinations*, anger, suicidal ideation*, mood altered, mood swings, restlessness, tearfulness, tics*, worsening of pre-existing tics or Tourette's syndrome*, hypervigilance, sleep disorder|
|Rare:||mania*, disorientation, libido disorder|
|Very rare:||suicidal attempt (including completed suicide)*, transient depressed mood*, abnormal thinking, apathy, repetitive behaviours, over-focussing|
|Not known:||delusions*, thought disturbances*, confusional state, dependence|
|Cases of abuse and dependence have been described, more often with immediate release formulations (frequency not known)|
|Nervous system disorders|
|Common:||dizziness, dyskinesia, psychomotor hyperactivity, somnolence|
|Very rare:||convulsions, choreo-athetoid movements, reversible ischaemic neurological deficit Neuroleptic malignant syndrome (NMS; Reports were poorly documented and in most cases, patients were also receiving other drugs, so the role of methylphenidate is unclear)|
|Not known:||cerebrovascular disorders* (including vasculitis, cerebral haemorrhages, cerebrovascular accidents, cerebral arteritis, cerebral occlusion), grand mal convulsions*, migraine|
|Uncommon:||diplopia, blurred vision|
|Rare:||difficulties in visual accommodation, mydriasis, visual disturbance|
|Common:||arrhythmia, tachycardia, palpitations|
|Very rare:||cardiac arrest, myocardial infarction|
|Not known:||supraventricular tachycardia, bradycardia, ventricular extrasystoles, extrasystoles|
|Very rare:||cerebral arteritis and/or occlusion, peripheral coldness, Raynaud's phenomenon|
|Respiratory, thoracic and mediastinal disorders|
|Common:||cough, pharyngolaryngeal pain|
|Common:||abdominal pain, diarrhea, nausea, stomach discomfort and vomiting, dry mouth|
|Uncommon:||hepatic enzyme elevations|
|Very rare:||abnormal liver function, including hepatic coma|
|Skin and subcutaneous tissue disorders|
|Common:||alopecia, pruritus, rash, urticaria|
|Uncommon:||angioneurotic oedema, bullous conditions, exfoliative conditions|
|Rare:||hyperhidrosis, macular rash, erythema|
|Very rare:||erythema multiforme, exfoliative dermatitis, fixed drug eruption|
|Musculoskeletal and connective tissue disorders|
|Uncommon:||myalgia, muscle twitching|
|Very rare:||muscle cramps|
|Renal and urinary disorders|
|Reproductive system and breast disorders|
|General disorders and administration site conditions|
|Common:||pyrexia, growth retardation during prolonged use in children*|
|Uncommon:||chest pain, fatigue|
|Very rare:||sudden cardiac death*|
|Not known:||chest discomfort, hyperpryrexia|
|Common:||changes in blood pressure and heart rate (usually an increase) *, weight decreased|
|Uncommon:||cardiac murmur*, hepatic enzyme increased|
|Very rare:||blood alkaline phosphatase increased, blood bilirubin increased, platelet count decreased, white blood count abnormal|
Signs and symptomsAcute overdose, mainly due to overstimulation of the central and sympathetic nervous systems, may result in vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, psychosis, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis and dryness of mucous membranes.
TreatmentThere is no specific antidote to methylphenidate overdosage.Treatment consists of appropriate supportive measures.The patient must be protected against self injury and against external stimuli that would aggravate overstimulation already present. If the signs and symptoms are not too severe and the patient is conscious, gastric contents may be evacuated by induction of vomiting or gastric lavage. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. In the presence of severe intoxication, a carefully titrated dose of a benzodiazepine should be given before performing gastric lavage.Intensive care must be provided to maintain adequate circulation and respiratory exchange; external cooling procedures may be required for hyperpyrexia.Efficacy of peritoneal dialysis or extracorporeal haemodialysis for overdose of methylphenidate has not been established.
|Placebo (N=39)a||Immediate Release Methylphenidate (N=120)b||Equasym XL (N=120)|
|Baseline Mean (SD)||6.0 (3.64)||6.1 (3.74)||5.8 (3.59)|
|LS Mean (SE)||7.7 (0.50)||4.3 (0.29)||4.5 (0.29)|
|95% CI||6.69, 8.66||3.71, 4.84||3.98, 51.0|
|Difference from Placebo||-||-3.4||-3.1|
|95% CI for the difference||-||-4.53, -2.26||-4.26, -2.00|
|Difference from MIR||-||-||-0.3|
|97.5% lower CI bound for the difference||-||-||-1.06|
|a N=38 at Day 7; b N=118 at Day 7; c Treatment groups have been compared using ANCOVA, with effects for treatment and baseline as covariates|
CarcinogenicityIn life-time rat and mouse carcinogenicity studies, increased numbers of malignant liver tumours were noted in male mice only. The significance of this finding to humans is unknown.Methylphenidate did not affect reproductive performance or fertility at low multiples of the clinical dose.
Pregnancy-embryonal/fetal developmentMethylphenidate is not considered to be a teratogenic in rats and rabbits. Fetal toxicity (i.e. total litter loss) and maternal toxicity was noted in rats at maternally toxic doses.
Sugar Spheres:SucroseMaize starchPovidone K29 to K32Opadry Clear YS-1-7006 (hypromellose, macrogol 400 and macrogol 8000)Ethylcellulose Aqueous DispersionDibutyl Sebacate
Capsule shellGelatinTitanium dioxide (E171)Indigo carmine aluminium salt (E132)10 mg capsules only: Yellow iron oxide (E172); 30 mg capsules only: Red iron oxide (E172)
White printing ink:ShellacPropylene glycolSodium hydroxidePovidone K16Titanium dioxide (E171)
Black printing ink:Shellac glaze 45% (20% esterified) in ethanolPropylene glycolAmmonium hydroxide 28%Iron oxide black
|Pack sizes:||10 modified-release capsules, hard.|
|28 modified-release capsules, hard.|
|30 modified-release capsules, hard.|
|60 modified-release capsules, hard.|
|100 modified-release capsules, hard (10 mg and 20 mg Capsules only)|
Shire Pharmaceuticals Limited
Hampshire International Business Park, Chineham, Basingstoke, Hampshire, RG24 8EP
+44 (0) 8000 556 614
+44 (0)1256 894 107
+44 (0)1256 894 000